Ian Somaiya

Ian Somaiya joined NewAmsterdam as Chief Financial Officer in October 2023. Mr. Somaiya has over 25 years of experience in finance and biotechnology. Most recently, he was Chief Financial and Business Officer at Elucida Oncology, where he was responsible for fund raising and overall corporate strategy. At TCR2 Therapeutics, he successfully navigated the company through its IPO and two follow-on financings, raising more than $350 million. During his nearly four years at TCR2, he led the company’s finance and public company reporting as well as business development and investor relations functions.

Prior to joining TCR2, Mr. Somaiya spent over 20 years on Wall Street where he conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. He was Managing Director and Head of Biotechnology Research at BMO Capital Markets, and served as a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Piper Jaffray Companies and Thomas Weisel Partners Group, Inc. He launched his Wall Street career as a research analyst at Morgan Stanley and Prudential Securities and was recognized as the “Best on the Street” by The Wall Street Journal for his coverage on biotechnology in 2006, 2007 and 2009. Mr. Somaiya received a Bachelor of Arts degree in Biology and Neuroscience from New York University.